SGK1 mediates TGF-β1-induced epithelial-mesenchymal transition and fibrosis in experimental bronchiolitis obliterans
Abstract
Bronchiolitis obliterans (BO) represents a major complication limiting long-term survival after lung transplantation, with epithelial-mesenchymal transition (EMT) serving as a core pathogenic mechanism. The TGF-β1 signaling pathway plays a critical role in EMT induction and can activate serum/glucocorticoid-regulated kinase 1 (SGK1) expression. While SGK1 is upregulated in various fibrotic diseases, its functional significance in BO remains undefined. To elucidate SGK1’s role in post-transplant BO fibrosis and its interaction with the TGF-β1 pathway, we established a murine heterotopic tracheal transplantation model. Histopathological evaluation and RNA sequencing demonstrated significant SGK1 upregulation in BO lesions by day 28. In vitro, both pharmacological inhibition (EMD638683) and genetic knockdown of SGK1 (siRNA) attenuated TGF-β1-induced EMT in the human small airway epithelial cell line (HSAECs), while concurrently suppressing the expression of extracellular matrix genes (COL1 and FN1). Furthermore, SGK1 inhibition reduced TGF-β1-induced SMAD2/3 phosphorylation. Therapeutic administration of EMD638683, initiated after disease establishment, significantly ameliorated BO pathology. These findings demonstrate that SGK1 promotes BO-associated fibrosis through TGF-β1-mediated EMT and ECM deposition, identifying SGK1 as a potential therapeutic target for post-transplant BO intervention.
Related
- Partial epithelial-to-mesenchymal transition mediates profound gap closure through growth and fluidization
- JAK3-Mediated Structural Remodeling of β-Catenin Suppresses Epithelial-Mesenchymal Transition: Insights from In Silico Modeling.
- RCCD1-JMJD5 coordinate histone demethylation to promote platinum resistance in non-small cell lung cancer via FN1-mediated epithelial-mesenchymal transition.
- DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy
- TENASCIN-Dependent Mesenchymal–Epithelial Interactions Associated with Interstitial Microenvironment Remodeling in Cattle-Yak Lung: Insights from Single-Nucleus Transcriptomics
BibTeX
@article{li2026sgk1,
title = {{SGK1 mediates TGF-β1-induced epithelial-mesenchymal transition and fibrosis in experimental bronchiolitis obliterans}},
author = {Hongwei Li and Li Zhao and Shihui Xu and Sixiang Tang and Junxing Lin and Yingjie Hu and Xiaowen Chen and Chengyu Lu and Dehui Chen},
journal = {iScience},
year = {2026},
month = oct,
doi = {10.1016/j.isci.2026.117961},
url = {https://www.cell.com/iscience/fulltext/S2589-0042(26)03344-4},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - SGK1 mediates TGF-β1-induced epithelial-mesenchymal transition and fibrosis in experimental bronchiolitis obliterans
AU - Hongwei Li
AU - Li Zhao
AU - Shihui Xu
AU - Sixiang Tang
AU - Junxing Lin
AU - Yingjie Hu
AU - Xiaowen Chen
AU - Chengyu Lu
AU - Dehui Chen
PY - 2026
DA - 2026/10/19
JO - iScience
DO - 10.1016/j.isci.2026.117961
UR - https://www.cell.com/iscience/fulltext/S2589-0042(26)03344-4
AB - Bronchiolitis obliterans (BO) represents a major complication limiting long-term survival after lung transplantation, with epithelial-mesenchymal transition (EMT) serving as a core pathogenic mechanism. The TGF-β1 signaling pathway plays a critical role in EMT induction and can activate serum/glucocorticoid-regulated kinase 1 (SGK1) expression. While SGK1 is upregulated in various fibrotic diseases, its functional significance in BO remains undefined. To elucidate SGK1’s role in post-transplant BO fibrosis and its interaction with the TGF-β1 pathway, we established a murine heterotopic tracheal transplantation model. Histopathological evaluation and RNA sequencing demonstrated significant SGK1 upregulation in BO lesions by day 28. In vitro, both pharmacological inhibition (EMD638683) and genetic knockdown of SGK1 (siRNA) attenuated TGF-β1-induced EMT in the human small airway epithelial cell line (HSAECs), while concurrently suppressing the expression of extracellular matrix genes (COL1 and FN1). Furthermore, SGK1 inhibition reduced TGF-β1-induced SMAD2/3 phosphorylation. Therapeutic administration of EMD638683, initiated after disease establishment, significantly ameliorated BO pathology. These findings demonstrate that SGK1 promotes BO-associated fibrosis through TGF-β1-mediated EMT and ECM deposition, identifying SGK1 as a potential therapeutic target for post-transplant BO intervention.
SN - 2589-0042
ER -